Abstract
Introduction: The SCAN lung cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for the use of adjuvant systemic therapy for non-small cell lung cancer in Singapore. Materials and Methods: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. Results: Five international guidelines were evaluated—those developed by the National Comprehensive Cancer Network (2014), European Society of Medical Oncology (2014), National Institute of Clinical Excellence (2012), Scottish Intercollegiate Guidelines Network (2014), and the Cancer Care Council Australia (2012). Recommendations on the selection of patients, chemotherapy regimen, treatment for stage I disease, treatment for positive margins and treatment options for pN2 disease with negative margins were produced. Conclusion: These adapted guidelines form the SCAN Guidelines 2015 for adjuvant systemic therapy of non-small cell lung cancer.
Key words: Decision-making, Postoperative therapy
Publisher
Academy of Medicine, Singapore
Reference20 articles.
1. Singapore Cancer Registry Interim Annual Registry Report Trends in Cancer Incidence in Singapore 2009-2013. National Registry of Disease Office. Health Promotion Board Singapore.
2. Singapore Cancer Registry Interim Annual Registry Report Trends in Cancer Incidence in Singapore 2008-2012. National Registry of Disease Office. Health Promotion Board Singapore.
3. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-60.
4. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 2005;352:2589-97.
5. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27.